Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 1
2019 1
2020 1
2021 1
2022 3
2023 2
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Hungria V, et al. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15. Lancet Haematol. 2025. PMID: 40680752 Clinical Trial.
[Dysphagia at Neutropenia of Unknown Primary].
Granitzka T, Inhestern JM, Yomade O, Guntinas-Lichius O. Granitzka T, et al. Among authors: yomade o. Laryngorhinootologie. 2016 Dec;95(12):851-852. doi: 10.1055/s-0042-117637. Epub 2016 Nov 16. Laryngorhinootologie. 2016. PMID: 27852094 German. No abstract available.
Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma.
Brioli A, Wyrwa A, Rüddel U, Yomade O, Lindig U, Franz W, Wacker HH, Gaßler N, Schweyer S, Chung HY, Axer H, Witte OW, Hochhaus A, Schrenk KG. Brioli A, et al. Among authors: yomade o. Ann Hematol. 2023 Jan;102(1):239-242. doi: 10.1007/s00277-022-05032-1. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401620 Free PMC article. No abstract available.
Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.
Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch JJ, Eigendorff F, Tober R, Schrenk KG, Hammersen JF, Yomade O, Hilgendorf I, Hochhaus A, Scholl S, Schnetzke U. Fleischmann M, et al. Among authors: yomade o. Ann Hematol. 2024 Dec;103(12):6061. doi: 10.1007/s00277-024-06095-y. Ann Hematol. 2024. PMID: 39562361 Free PMC article. No abstract available.
13 results